The increase of circulating CX3CR1+ CD8+ T cells was also observed in MC38 tumor-bearing mice treated with anti-PD-L1 therapy alone with improved tumor control and survival (Fig. 1g, h). This evidence concerns the gene CX3CR1 and neoplasm.